These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 31724803)

  • 1. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
    Burke MJ; Kostadinov R; Sposto R; Gore L; Kelley SM; Rabik C; Trepel JB; Lee MJ; Yuno A; Lee S; Bhojwani D; Jeha S; Chang BH; Sulis ML; Hermiston ML; Gaynon P; Huynh V; Verma A; Gardner R; Heym KM; Dennis RM; Ziegler DS; Laetsch TW; Oesterheld JE; Dubois SG; Pollard JA; Glade-Bender J; Cooper TM; Kaplan JA; Farooqi MS; Yoo B; Guest E; Wayne AS; Brown PA
    Clin Cancer Res; 2020 May; 26(10):2297-2307. PubMed ID: 31969338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
    Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
    Yeo KK; Gaynon PS; Fu CH; Wayne AS; Sun W
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):345-9. PubMed ID: 27352191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
    Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
    Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
    Parker C; Waters R; Leighton C; Hancock J; Sutton R; Moorman AV; Ancliff P; Morgan M; Masurekar A; Goulden N; Green N; Révész T; Darbyshire P; Love S; Saha V
    Lancet; 2010 Dec; 376(9757):2009-17. PubMed ID: 21131038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
    Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
    Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
    Messinger Y; Gaynon P; Raetz E; Hutchinson R; Dubois S; Glade-Bender J; Sposto R; van der Giessen J; Eckroth E; Bostrom BC
    Pediatr Blood Cancer; 2010 Aug; 55(2):254-9. PubMed ID: 20582937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia].
    Keino D; Ohyama R; Ashikaga T; Morimoto M; Yamashita A; Kondoh K; Kinoshita A
    Rinsho Ketsueki; 2014 Mar; 55(3):327-33. PubMed ID: 24681936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Nachmias B; Shaulov A; Gatt ME; Shapira M; Gural A
    Acta Haematol; 2018; 140(4):209-214. PubMed ID: 30343286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
    Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
    Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
    Thomson B; Park JR; Felgenhauer J; Meshinchi S; Holcenberg J; Geyer JR; Avramis V; Douglas JG; Loken MR; Hawkins DS
    Pediatr Blood Cancer; 2004 Oct; 43(5):571-9. PubMed ID: 15382275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007.
    Kozlowski P; Åström M; Ahlberg L; Bernell P; Hulegårdh E; Hägglund H; Karlsson K; Markuszewska-Kuczymska A; Tomaszewska-Toporska B; Smedmyr B; Hallböök H
    Haematologica; 2012 Sep; 97(9):1414-21. PubMed ID: 22511497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
    Nickel RS; Keller F; Bergsagel J; Cooper T; Daves M; Sabnis H; Lew G
    Pediatr Blood Cancer; 2014 May; 61(5):810-4. PubMed ID: 24357218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.
    Kaspers GJL; Niewerth D; Wilhelm BAJ; Scholte-van Houtem P; Lopez-Yurda M; Berkhof J; Cloos J; de Haas V; Mathôt RA; Attarbaschi A; Baruchel A; de Bont ES; Fagioli F; Rössig C; Klingebiel T; De Moerloose B; Nelken B; Palumbo G; Reinhardt D; Rohrlich PS; Simon P; von Stackelberg A; Zwaan CM
    Br J Haematol; 2018 May; 181(4):523-527. PubMed ID: 29676440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria.
    Ravichandran N; Uppuluri R; Swaminathan VV; Patel S; Ramanan KM; Jayakumar I; Ramakrishnan B; Raj R
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e212-e214. PubMed ID: 31688621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.